Dr. Reddy's Laboratories Launches Pregabalin Capsules in the US Market
31 July 2019 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Pregabalin Capsules, a therapeutic equivalent generic version of Lyrica (pregabalin) Capsules approved by the US Food and Drug Administration (USFDA) in the US market, the company said.

The Lyrica (pregabalin) Capsules brand had US sales of approximately USD 5,462m MAT for the most recent twelve months ending in May 2019 according to IQVIA Health.

Dr. Reddy's Pregabalin Capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90.

This is also a controlled substance schedule V product.

Dr. Reddy's Laboratories offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include USA, India, Russia and CIS countries, and Europe.